Early Detection Methods for Pancreatic Cancer
What You Need to Know Before You Apply
What is the purpose of this trial?
This trial aims to discover new methods for early detection of pancreatic cancer, particularly in high-risk individuals. Researchers will employ advanced computer techniques to analyze databases and images for early cancer indicators. The trial includes two groups: one with individuals having certain genetic conditions or family histories of pancreatic cancer, and another with individuals having a family history of pancreatic cancer or specific gene mutations. This trial may suit those with a strong family history of pancreatic cancer or who carry certain gene mutations linked to cancer. As an unphased trial, it offers participants the chance to contribute to groundbreaking research that could lead to earlier detection methods for pancreatic cancer.
Do I need to stop my current medications for the trial?
The trial information does not specify whether you need to stop taking your current medications.
What prior data suggests that these early detection methods for pancreatic cancer are safe?
Research has shown that the methods used in this study, such as blood sampling, pancreatic juice collection, and MRI scans, are generally well-tolerated. Blood collection is a routine and safe procedure used in many medical tests. Similarly, pancreatic juice collection employs safe, established methods.
MRIs, commonly used for imaging, have a strong safety record. They use magnetic fields and radio waves to create body images and do not involve radiation. Studies have demonstrated that MRIs effectively detect early signs of pancreatic cancer, especially in high-risk individuals, without causing significant side effects.
Overall, these procedures have been well-tolerated in past research, which has not reported any major safety concerns.12345Why are researchers excited about this trial?
Researchers are excited about this trial because it aims to identify individuals at high risk for pancreatic cancer using a detailed registry approach. Unlike current options, which primarily focus on treating the disease after it develops, this trial concentrates on early detection and prevention. By stratifying participants into different risk tiers based on their genetic background and family history, it provides a more personalized approach to monitoring and potentially intervening before pancreatic cancer develops. This proactive strategy could significantly shift the focus from treatment to prevention, offering hope for earlier interventions and better outcomes for those at risk.
What evidence suggests that this trial's methods could be effective for early detection of pancreatic cancer?
This trial will evaluate early detection methods for pancreatic cancer, including MRI scans. Studies have shown that MRI can identify early signs of the disease in high-risk individuals. Research involving more than 3,000 high-risk individuals found that MRI can detect early pancreatic cancer. Specifically, MRI helps identify precancerous lesions—abnormal tissues that might develop into cancer—and early-stage cancers in the pancreas. In one study, individuals diagnosed early through screening had a five-year survival rate of 73.3%, significantly higher than usual rates. This suggests that MRI can be a powerful tool in catching pancreatic cancer early, potentially improving survival chances.678910
Who Is on the Research Team?
Shounak Majumder, M.D.
Principal Investigator
Mayo Clinic in Rochester
Are You a Good Fit for This Trial?
Inclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Surveillance
Participants undergo regular screening and surveillance tests, including radiology imaging and endoscopic procedures
Follow-up
Participants are monitored for safety and effectiveness of early detection methods
What Are the Treatments Tested in This Trial?
Interventions
- Bio-specimen Collection: Blood
- Bio-specimen Collection: Pancreatic Juice
- MRI
How Is the Trial Designed?
2
Treatment groups
Experimental Treatment
* Individual with family history of PDAC in only one first degree relative (FDR); age ≥50 or 10 years younger than the affected first degree relative * OR known BRCA2, BRCA1, PALB2, ATM, MLH1, MSH2, or MSH6 gene mutation; age \> 45 who do not meet tier 1 criteria.
* Participants with Peutz-Jeghers syndrome and/or carriers of a germline CDKN2A mutation and/or hereditary pancreatitis with PRSS1 mutation and clinical history of pancreatitis(age ≥40 or 10 years younger than youngest affected blood relative) * Carriers of a germline BRCA2, BRCA1, PALB2, ATM, MLH1, MSH2, or MSH6 gene mutation with at least one affected first-degree blood relative (age ≥45 or 10 years younger than youngest affected blood relative) * At least one first-degree relative (FDR) with pancreatic cancer who in turn also has a first-degree relative with pancreatic cancer and/or at least two affected blood relatives on the same side of the family, of whom at least one is an FDR to the individual and/or at least three affected relatives on the same side of the family, of whom at least one is an FDR to the individual(age ≥50 or 10 years younger than youngest affected blood relative)
Find a Clinic Near You
Who Is Running the Clinical Trial?
Mayo Clinic
Lead Sponsor
Citations
Screening for pancreatic cancer in high-risk individuals ...
Various MRI sequences aid in the detection of pancreatic lesions, but they also detect secondary signs such as stenosis and dilatation of the ...
Recommendations, evidence and sustainability of ...
This review evaluates current recommendations for pancreatic cancer surveillance in high-risk individuals, synthesises evidence from recent studies and explores ...
Pancreatic Cancer Surveillance and Survival of High-Risk ...
Using EUS, MRI, and/or CT, 25 surveillance studies involving more than 3000 high-risk individuals showed that early detection of asymptomatic PDAC is feasible.
Surveillance for People at High Risk of Pancreatic Cancer
Researchers are using MRI scans to check the pancreas for precancerous lesions and early-stage pancreatic cancers in people at high risk for the disease.
The Multicenter Cancer of Pancreas Screening Study
Five-year survival to date of the patients with a screen-detected PDAC is 73.3%, and median overall survival is 9.8 years, compared with 1.5 ...
Standard Operating Procedures for Biospecimen Collection ...
High quality and well-annotated biorepositories are needed to better understand the pathophysiology and biologic mechanisms of chronic pancreatitis (CP) and ...
Pancreatic Cancer Early Detection Consortium (PRECEDE)
The PRECEDE Consortium is an observational prospective cohort study, with single or serial biosample collection (every 6-12 months) in defined high-risk groups.
Challenges of early detection of pancreatic cancer
This led to the development of the Avantect Pancreatic Cancer Test, for which a recent validation study showed 68.3% sensitivity (95% CI: 51.9%– ...
9.
mayo.edu
mayo.edu/research/centers-programs/pancreatic-cancer-early-detection-research-program/overviewPancreatic Cancer Early Detection Research Program
Our teams have developed blood, cyst fluid and pancreatic juice biomarkers for detection of early pancreatic cancer and advanced-stage precursor lesions, ...
NCT06151223 | A Prospective Registry for Patients at High ...
This study aims to facilitate discovery and validation of tests for early detection in subjects at high risk for pancreatic ductal adenocarcinoma (PDAC) and ...
Unbiased Results
We believe in providing patients with all the options.
Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.
Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.